Fig. 4.

Combination of ARQ 092 and ARQ 087 exerted enhanced antitumor activity in AN3CA cells. (a) Mice bearing AN3CA cells were dosed with ARQ 092 at 50, 75, or 100 mg/kg or ARQ 087 at 50 and 75 mg/kg as single agents or combination orally once daily for 12 days (n=10). (b) Body weight loss of mice bearing AN3CA cells was recorded during the dosing period. (c) Mice bearing human endometrial PDX models ST413 (PIK3CAH1047R and FGFR1E486Q&L417R) and ST259 (PIK3CAR93W&D350G and FGFR4V10I&P136L) were dosed with ARQ 092 at 100 mg/kg (n=3) or ARQ 087 at 75 g/kg (n=3) or combination (n=5) in a schedule of 4 days on and 3 days of for four cycles. The statistical significance as shown in comparison with the vehicle group (*P<0.05; **P<0.01).